Chris Cameron, PhD
Chief Scientific Officer
Expertise:
Dr. Chris Cameron is a global thought leader in health economics and outcomes research with over a decade of experience. Prior to joining EVERSANA, Chris was a partner at Cornerstone Research Group Inc., and lead of Health Economics at CADTH. He has also been a consultant decision scientist for ICER, a member of the Economic Guidance Panel at pCODR, and served on PMPRB Technical Panel on drug pricing guidelines in Canada. Chris is an adjunct (scholar) professor at Dalhousie University, and has authored over 100 peer-reviewed publications in many of the world’s top journals, including JAMA, Lancet, and BMJ. His research has been featured in the Globe and Mail and New York Times. He was recently named one of the most prolific authors in the world on indirect treatment comparisons, and was a co-author on the PRISMA NMA reporting guidelines.
Chris holds a bachelor’s degree in Mathematics and an MSc and PhD in Epidemiology where he was a Vanier Canada Graduate Scholar. He also completed a fellowship on real-world data analytics at Harvard University and FDA’s Sentinel Initiative, and the Oxford Artificial Intelligence Programme.
Articles by Chris Cameron, PhD
Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs
Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs The Institute for Clinical and Economic Review (ICER) has recently updated its protocol for assessing unsupported price increases of prescription drugs. This initiative provides a transparent and systematic approach to evaluate whether substantial price hikes in medications in the United States are justified […]
Empowering Success: EVERSANA’s Value & Evidence Team Guides Clients Through CMS Drug Negotiations Under the Inflation Reduction Act
Authors: Chris Cameron, Kerise Clarke, Barkha Patel, Amanda Griffin In anticipation of CMS’s announcement of the first 10 drugs to be selected for negotiations through the Inflation Reduction Act on September 1, 2023, we partnered to support our clients as they faced the prospect of selection. Our engagement began well before the announcement date to […]
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
EVERSANA’s Value & Evidence (V&E) and Data & Analytics (D&A) team collectively had an impressive 27 abstracts accepted to ISPOR U.S. 2023, showcasing EVERSANA’s ability to cross-solve for clients’ HEOR needs. EVERSANA’s Value & Evidence and Data & Analytics teams have had 27 abstracts accepted to ISPOR U.S. 2023, the leading global conference for health […]
ISPOR 2020 WORKSHOP: Developing Global Indirect Treatment Comparison Programs for Market Access
DEVELOPING AND IMPLEMENTING AN INDIRECT TREATMENT COMPARISON (ITC) PROGRAM TO SUPPORT GLOBAL HEALTH TECHNOLOGY ASSESSMENT (HTA) AND REIMBURSEMENT SUBMISSIONS Virtual ISPOR 2020 | WEDNESDAY, May 20th, 2020 | 10:00 AM ET PURPOSE: This interactive workshop will examine the various indirect comparison methodologies that are available. Commonly used ITC methods such as network meta-analysis (NMA) and matching-adjusted […]
ISPOR 2020 PODIUM: PSM and Bayesian Hierarchical Design Methods to Integrate Single-Arm Studies into NMAs in Lung Cancer
APPLICATION OF PROPENSITY SCORE MATCHING AND BAYESIAN HIERARCHICAL DESIGN METHODS TO INTEGRATE SINGLE-ARM STUDIES INTO NETWORK META-ANALYSES (NMAS): Opportunities and Pitfalls Illustrated in a Case Study Assessing Ablation/Radiation Therapies in Lung Cancer Virtual ISPOR 2020 | TUESDAY, May 19th, 2020 | 5:45-6:00 PM ET OBJECTIVES: Network meta-analyses (NMAs) generally include direct comparative evidence from randomized […]
ISPOR 2020 PODIUM: Methodological Challenges with NMAs Assessing Long-term Efficacy in Psoriasis
METHODOLOGICAL CHALLENGES WITH CONDUCTING NETWORK META-ANALYSES ASSESSING LONG-TERM COMPARATIVE EFFICACY IN PSORIASIS- A CRITIQUE OF ASSUMPTIONS UNDERPINNING RECENT INDIRECT TREATMENT COMPARISONS Virtual ISPOR 2020 | TUESDAY, May 19th, 2020 | 5:30-5:45 PM ET OBJECTIVES: In network meta-analysis (NMA) of psoriasis trials, cross-over after an initial placebo-controlled period limits the connectivity of long-term evidence networks. We illustrate […]